Merck (MRK) Retained Earnings (2009 - 2026)
Merck (MRK) reported Retained Earnings of $66.7 billion for Q1 2026, up 1443.83% year-over-year from $4.3 billion in Q1 2025, and down 8.7% quarter-over-quarter from $73.1 billion in Q4 2025.
Merck (MRK) Retained Earnings (2009 - 2026) Analysis & Trends
Merck (MRK) has 18 years of Retained Earnings data on file, last reported at $66.7 billion in Q1 2026.
- Retained Earnings for Q1 2026 came in at $66.7 billion, up 1443.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $66.7 billion (up 1443.83% YoY), and the FY2025 annual result was $73.1 billion, up 1577.76% from the prior year.
- Retained Earnings retreated to $66.7 billion in Q1 2026 per MRK's latest filing, from $73.1 billion in the prior quarter.
- Over five years, Retained Earnings peaked at $73.1 billion in Q4 2025 and troughed at -$5.4 billion in Q2 2024.
- A 5-year average of $38.4 billion and a median of $56.3 billion in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings sank 109.89% in 2024, then jumped 1577.76% in 2025.
- A 5-year view of Retained Earnings shows it stood at $61.1 billion in 2022, then slipped by 11.76% to $53.9 billion in 2023, then sank by 109.18% to -$4.9 billion in 2024, then soared by 1577.76% to $73.1 billion in 2025, then slipped by 8.7% to $66.7 billion in 2026.
- Business Quant data shows MRK's Retained Earnings at $66.7 billion in Q1 2026, $73.1 billion in Q4 2025, and $72.2 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 1.90 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 29.51 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | -14.83 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -17.87 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 66.72 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -190.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 78.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -7.20 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -1.37 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 66.72 Bn |
| Dec 31, 2025 | 73.08 Bn |
| Sep 30, 2025 | 72.23 Bn |
| Jun 30, 2025 | 68.48 Bn |
| Mar 31, 2025 | -4.97 Bn |
| Dec 31, 2024 | -4.95 Bn |
| Sep 30, 2024 | 61.38 Bn |
| Jun 30, 2024 | -5.36 Bn |
| Mar 31, 2024 | -5.27 Bn |
| Dec 31, 2023 | 53.90 Bn |
| Sep 30, 2023 | 57.08 Bn |
| Jun 30, 2023 | 54.20 Bn |
| Mar 31, 2023 | -4.88 Bn |
| Dec 31, 2022 | 61.08 Bn |
| Sep 30, 2022 | -4.74 Bn |
| Jun 30, 2022 | 58.44 Bn |
| Mar 31, 2022 | 56.25 Bn |
| Dec 31, 2021 | 53.70 Bn |
| Sep 30, 2021 | 51.69 Bn |
| Jun 30, 2021 | -4.63 Bn |